

Laufende Klinische Studien

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	PI	Co- Investigator	Status / Start / End
Prof. Dr. Dagmar Simon						
Urticaria	CDX0159-12	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (Embarq – CSU1)	PPD	Prof. Simon	S. Radonjic	in Planung
Atopische Dermatitis	Incyte_TRuE-AD4 INCB 1824_326	Topical Ruxolitinib Evaluation in Atopic Dermatitis Study (TRuE-AD4) A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis.	Incyte Corporation	Prof. Simon		in Planung
Prurigo Nodularis	INCB54707-305	Povorcitinib	Incyte Corporation	Prof. Simon		in Planung
Prurigo Nodularis	Amgen_20230053	Rocatinlimab	Amgen	Prof. Simon		in Planung
Atopische Dermatitis	ADHope 2 M-1723-34	Phase 3b Studie zu Lebrikizumab (antiIL-13) bei Atopic Dermatitis	Almirall	Prof. Simon		in Planung

Dermatologische Klinik Inselspital Bern

Studienübersicht

Atopische Dermatitis	TREAT	Treatment and medical care of patients with moderate-to-severe atopic dermatitis - Swiss national clinical registry TREAT Switzerland	SGDV	Prof. Simon		Rekrutiert Patienten
----------------------	-------	---	------	-------------	--	----------------------

Prof. Dr. Robert Hunger						
Hidradenitis suppurativa	M23-698	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy	Abbvie	Prof. Hunger		Rekrutiert Patienten
Advanced Cutaneous Squamous Cell Carcinoma	CemiSkin	Nichtinterventionelle multizentrische, longitudinale 2-Kohorten Studie zur Wirksamkeit, Sicherheit und Quality of Life (QoL) bei Patienten mit fortgeschrittenem kutanen Plattenepithelkarzinom (adCSCC, Advanced Cutaneous Squamous Cell Carcinoma), die mit Cemiplimab (prospektive Kohorte) oder anderen Therapieansätzen behandelt werden	Sanofi-Aventis	Prof. Hunger	Dr. Benzaquin	Rekrutiert Patienten
Melanoma	NEO-DREAM	An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients	Philochem	Prof. Hunger		Rekrutiert Patienten
Melanoma	BERING_MELANOMA	Encorafenib + Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma ; a multi-centric, national, prospective, longitudinal, non-interventional study in Switzerland Binimetinib plus Encorafenib Real life Investigation of Next Generation Melanoma treatment	Pierre Fabre Pharma AG/Alcedis	Prof. Hunger	Dr. Lamos Dr. Bossart	Rekrutiert Patienten
Hidradenitis suppurativa	HS Register	The goal of the Hidradenitis suppurativa registry (HSR) is to evaluate the long-term course, safety clinical outcomes and health related quality of life of patients with Hidradenitis suppurativa (HS). Patient will be enrolled in the HSR with a confirmed HS diagnosis only and treated in the participating centers. Patients will remain in the HSR for 3 years, regardless of subsequent therapy.	SHSF	Prof. Hunger		Rekrutiert Patienten

Prof. Dr. Nikhil Yawalkar	
---------------------------	--

Dermatologische Klinik Inselspital Bern Studienübersicht

Paradoxical Psoriasis	TYPP/TYK2	TYK2 inhibition in paradoxical psoriasis (TYPP) A randomized, double-blind, placebo-controlled multi-center study evaluating the effect of Deucravacitinib on severity of psoriasis in patients with paradoxical psoriasis (phase II/III)	CHUV	Prof. Yawalkar		in Planung
Genital Psoriasis	CzATCH	Observational, non-interventional, prospective, multinational (Austria, Switzerland, and the Czech Republic), multicentric, open, uncontrolled study on the effectiveness and safety of Tildrakizumab in the treatment of plaque psoriasis with a manifestation in the genital area in clinical routine according to the summary of product characteristics (SmPC).	Almirall/ CW Research & Management	K. Heidemeier	Prof. Yawalkar A. Rabuffetti	Rekrutiert Patienten
Psoriasis (GPP)	SPESOLIMAB (Compassionate Use Program)	Open label expanded access program (EAP) or compassionate use program (CUP) or named patient use (NPU) of intravenous Spesolimab 900 mg in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare	Boehringer Ingelheim	Prof. Yawalkar / K. Heidemeyer	Dr. Heidemeyer	Rekrutiert Patienten
Psoriasis vulgaris	SDNTT	Psoriasis Register-Studie / Long-Term Benefits of Systemic Psoriasis Therapy	SGDV & Uni Zürich	Prof. Yawalkar	diverse Ärzte siehe separate Liste	Rekrutiert Patienten
Weitere						
Chronic Pruritus	CP-derma1	Multicenter case-control study on risk factors for generalised chronic pruritus , with focus on patients' comorbidities and medications intake		Dr. Cazzaniga	Dr. Benzaquen	Rekrutiert Patienten
Hidradenitis suppurativa	PROSPECT	A prospective Analysis of patients with Hidradenitis suppurativa		Dr. Morteza		in Planung